

Asia Pacific Oncology Summit (APOS) 2017

12-13 AUGUST 2017 | Taipei, Taiwan

APOS 2017 overall objectives

- To bring together oncologists and healthcare professionals from across the Asia Pacific region for high-quality scientific and educational sessions
- To provide a platform for a world-class faculty of international and regional experts for discussion around ground-breaking research and important clinical updates in the management of breast cancer (BC), metastatic renal cell carcinoma (mRCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), with a focus on the Asian population
- To promote the sharing of knowledge and best practices in the management of cancer through the interactive discussions of real-world patient cases
- To consider and discuss the practical and regulatory issues surrounding the utility and management of biologic therapy in oncology

主辦單位: 中華民國癌症醫學會/ 輝瑞大藥廠股份有限公司

Agenda

DAY 1 12 AUGUST 2017		
09:00–09:30	Registration	
09:30–09:40 (10 min)	Welcome and opening remarks Highlights from APOS 2016	Ann-Lii Cheng (Taiwan)
KEYNOTE SESSION		Session co-chairs: Ann-Lii Cheng & James Yang (Taiwan)
09:40–10:55 (~25 min each)	What does “good” look like? Overarching talks: Burden of disease, epidemiology, unmet needs/gaps, advocacy issues, challenges/barriers and opportunities 1. Revolutionizing HR+ mBC 2. Navigating the RCC treatment landscape 3. Conquering lung cancer: Successes we have achieved so far	1. Kim Blackwell (USA) 2. Tom Hutson (USA) 3. Robert Doebele/ Ignatius Ou (USA)
10:55–11:15 (20 min)	Panel discussion	
11:15–11:45 (30 min)	The next 10 years: Redefining the cancer landscape in the next decade • How would the cancer landscape look like in the next decade • What are the targetable pathways in oncology – encompassing journey with CDK4/6, PI3K, etc. • What is the Pfizer Oncology clinical development program?	Mahmood Alam (Pfizer) Charles-Hugh Jones (Pfizer)
11:45–12:00 (15 min)	Q&A	
12:00–13:00	LUNCH	
PLENARY SESSION I		Session co-chairs: Ming-Feng Hou & Yu-Ming, Chen (Taiwan)
13:00–13:30 (30 min)	Evidence – the US experience with CDK4/6 inhibitors • Experience-sharing with CDK4/6 inhibitors in mBC, with case study presentation	Kim Blackwell (USA)
13:30–14:00 (30 min)	“Richness of choices” available in kidney cancer, but patient selection is key • Points consideration when deciding appropriate therapeutic agents	Tom Hutson (USA)

	for first- and second-line treatment in kidney cancer		
	<ul style="list-style-type: none">Treatment selection criteria (eg, patient profile, risk factors, patient preference)		
14:00–14:10 (10 min)	Q&A		
14:10–14:40 (30 min)	Multidisciplinary diagnosis and treatment of lung cancer in the era of molecular medicine <ul style="list-style-type: none">Role of molecular profiling-based treatment strategies in lung cancerMultimodality management of lung cancer		Tony Mok (Hong Kong)
14:40–14:55 (15 min)	Q&A		
14:55–15:00 (5 min)	Introduction to breakout session		Ming-Feng Hou (Taiwan)
15:00–15:20	BREAK		
BREAKOUT SESSION			
	Tumor board: RCC	Tumor board: NSCLC	Tumor board: BC
	Thomas Hutson & Tai-Lung Cha	Tony Mok & Jin-Yuan Shih	Shyr-Ming Sheen Chen/Chiun-Sheng, Huang
15:20–15:30 (10 min)	Introductions	Introductions	
15:30–17:20 (110 min)	<ol style="list-style-type: none">Long-term survivorship in mRCC: What can we learn from the real-world experience? <IND KOL>Challenges in dose optimization in the first-line treatment of mRCC: Lessons we have learnt so far Jian-Ri Li (Taiwan)Perspectives and rationale in second-line mRCC treatment <IND KOL>Current evidence and practical approaches in managing early RCC patients Yen-Hwa Chang(Taiwan)	<ol style="list-style-type: none">What can we learn from real-world experience: ALK+ NSCLC <HK KOL>What can we learn from real-world experience: ROS1+ NSCLC <IND KOL>Optimal management of brain metastasis with oncogene-addicted diseases <THA KOL>Optimizing the patient journey in advanced NSCLC: Building a strategy for success in the new era Chao-Hua Chiu (Taiwan)	<ol style="list-style-type: none">Early BC: Role of hormonal therapy Prue Francis (Australia)Use of anthracyclines in early BC Liang-Chih Liu (Taiwan)First-line HR+ HER2- mBC clinical study – experience from India <IND KOL>De novo HR+ HER2- mBC diagnosis with low-volume visceral disease – what to do? <SGP/HK KOL>TNBC: Current treatment strategies and role of PARP inhibitors Rebecca Dent (Singapore)
17:20–17:30 (10 min)	Recap and key takeaways	Recap and key takeaways	Recap and key takeaways
17:30	Day 1 close		
19:00 onwards	APOS DINNER & DISCUSSION		

DAY 2 13 AUGUST 2017		
08:30–09:00	Registration	
09:00–09:10 (10 min)	Opening remarks and Day 1 recap	Pan-Chyr Yang (Taiwan)
PLENARY SESSION II		Session chair: Kun-Huei Yeh (Taiwan)
09:10–09:40 (30 min)	The changing landscape of colorectal cancer <ul style="list-style-type: none"> • Current treatment options and change in the treatment landscape with the introduction of targeted agenda and identification of biomarkers • Key data on irinotecan and its position in current therapy • Management consideration on disease progression and therapy sequencing 	Yi Hsin Liang (Taiwan)
09:40–09:50 (10 min)	Q&A	
09:50–10:15 (25 min)	Lead or be led on biosimilars? <ul style="list-style-type: none"> • Role of biosimilars on addressing issues on healthcare affordability profiling and patient access to treatment • Opportunities of biosimilars • Role of clinicians (vs government) in leading the conversation on increasing the uptake of biosimilars 	Paul Cornes (UK)
10:15–10:40 (25 min)	Emerging landscape of biosimilars in the Asia Pacific region <ul style="list-style-type: none"> • Use of biosimilars in APAC – barriers and challenges and ways to overcome • Addressing the quality, efficacy and safety of biosimilars • How are biosimilars approved? 	John Zalcborg (Australia)
10:40–10:50 (10 min)	Q&A	
10:50–11:10	BREAK	
PLENARY SESSION III		Session chair: Chair: Simon Hsieh (Taiwan)
11:10–11:45 (35 min)	Global and Asian context on improving mBC patient care by 2025 – mBC Decade Report <ul style="list-style-type: none"> • Interview-style forum • Overview of ‘Global Status of mBC: A Decade Report’ • Areas of improvement and gaps in care, access to resources and support, mBC treatment outcome 	Fatima Cardoso (Portugal) Gloria Lin (Taiwan BC Alliance)
11:45–12:15 (30 min)	Immuno-oncology: Issues and considerations <ul style="list-style-type: none"> • Role of immuno-oncology combinations in cancer • Efficacy and safety data on immuno-oncology combination therapy • Future outlook of immuno-oncology and other novel approaches 	Grant McArthur (Australia) / Pfizer
12:15–12:30 (15 min)	Q&A	
12:30–13:30	LUNCH	
13:30–13:50 (20 min)	A spotlight on the burden of cancer in Asia <ul style="list-style-type: none"> • Specific needs of Asian cancer patients • Epidemiology and prevalent tumors in Asia • Clinical trials in Asia 	<KOL>
13:50–14:05 (15 min)	Q&A	

Interactive forum		Session chair: Jerry, Cheng-Hsu Wang (Taiwan)
14:05–15:20 (75 min)	<p>Forum: Prioritizing strategies to address gaps in access to optimal patient cancer care</p> <ul style="list-style-type: none"> 10-min presentation (Goddard) – War on Cancer 2017: Findings and call-to-action 10-min presentation (Bhoo-Pathy) – Policy and priorities for affordable and equitable cancer care 40-min guided panel discussion on improving cooperation with multiple stakeholders in streamlining national cancer control plans, strengthening cancer healthcare infrastructure to improve equitable access to service and paving the way to broader access to innovative oncology treatment, all from an oncologist's perspective 10-min audience comments/Q&A 5-min wrap up (Goddard) 	<p><u>Moderator:</u> Charles Goddard (The EIU)</p> <p><u>Panelists:</u> Fatima Cardoso (Portugal) Ravi Kanesvaran (Singapore) K. Smruti/ Mohandas Mallath (India) Nirmala Bhoo-Pathy (Malaysia) John Chang (Taiwan) Kumar V (Pfizer)</p>
15:20–15:30 (10 min)	Summary and closing remarks	<p>Pan-Chyr Yang (Taiwan) Mahmood Alam (Pfizer)</p>
15:30	Meeting close	

Asia Pacific Oncology Summit (APOS) 2017

報 名 表 (2017/8/12-13)

**請務必填寫英文姓名。

Attendee Type (Pfizer Staff / Dr. / SPK)	Title	Given Name	Family Name	Preferred Name on Badge	Specialty	Job Title	Institution	Country
Doctor								Taiwan
12 Aug - Day 1 Keynote Section	12 Aug - Day 1 Plenary Session I	12 Aug - Day 1 Breakout Session (Renal Cell Carcinoma)	12 Aug - Day 1 Breakout Session (Non-Small Cell Lunge Cancer)	12 Aug - Day 1 Breakout Session (Breast Cancer)	12 Aug APOS dinner	13 Aug - Day 2 Plenary Session II	13 Aug - Day 2 Plenary Session III	13 Aug - Day 2 Interactive Forum
8/12 午餐 (素 / 葷 / X不用)	8/12 晚餐 (素 / 葷 / X不用)	8/13 午餐 (素 / 葷 / X不用)						